Valuation: REGENXBIO Inc.

Market Cap 434M 390M 360M 326M 610M 41.26B 618M 4.32B 1.71B 21.63B 1.63B 1.6B 68.58B P/E 2026 *
-2x
P/E 2027 * -2.45x
Enterprise Value 426M 382M 353M 320M 598M 40.43B 605M 4.23B 1.68B 21.19B 1.6B 1.56B 67.2B EV / Sales 2026 *
2.56x
EV / Sales 2027 * 2.38x
Free-Float
93.45%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: REGENXBIO Inc.

1 day+0.30%
1 week-10.81%
Current month-12.35%
1 month-11.65%
3 months-32.03%
6 months-23.43%
Current year-54.17%
1 week 6.46
Extreme 6.4586
7.47
1 month 6.46
Extreme 6.4586
8.31
Current year 5.46
Extreme 5.455
16.19
1 year 5.46
Extreme 5.455
16.19
3 years 5.04
Extreme 5.035
28.8
5 years 5.04
Extreme 5.035
40.59
10 years 5.04
Extreme 5.035
85.1
Manager TitleAgeSince
Chief Executive Officer 64 2024-06-30
Director of Finance/CFO 45 2024-09-15
Chief Tech/Sci/R&D Officer 53 2025-02-28
Director TitleAgeSince
Chairman 78 2020-06-30
Director/Board Member 76 2015-10-14
Director/Board Member 64 2024-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Tax

Chief Technology Officer

-234 0.0004%
9/1/26 Tax

Chief Financial Officer

-4,902 0.0074%
8/27/26 Buy

Director

53,407 0.0818%
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%-10.81%-51.54%-54.10% 434M
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+7.26%+11.51%+77.95% 54.57B
+0.16%+3.69%+8.39%+101.27% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+17.90%+56.87%+47.78% 26.5B
Average -0.55%+0.98%+36.13%+135.17% 38.37B
Weighted average by Cap. -0.73%+1.71%+42.94%+154.90%

Financials

2026 *2027 *
Net sales 166M 149M 138M 125M 233M 15.77B 236M 1.65B 655M 8.27B 623M 610M 26.21B 205M 184M 170M 154M 288M 19.47B 292M 2.04B 809M 10.21B 770M 753M 32.37B
Net income -185M -166M -153M -139M -260M -17.58B -263M -1.84B -730M -9.21B -695M -680M -29.22B -201M -181M -167M -151M -283M -19.11B -286M -2B -794M -10.01B -755M -739M -31.76B
Net Debt -8.72M -7.82M -7.23M -6.55M -12.25M -828M -12.4M -86.62M -34.4M -434M -32.73M -32.03M -1.38B 53.61M 48.12M 44.43M 40.29M 75.3M 5.09B 76.23M 533M 212M 2.67B 201M 197M 8.46B
Projected Income Statement - Annual - REGENXBIO Inc.
Logo REGENXBIO Inc.
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Employees
371
Date Price Change Volume
26-10-27 US$6.600 +0.30% 1,219,377
26-10-26 US$6.580 -1.50% 1,138,425
26-10-23 US$6.680 -6.83% 1,452,352
26-10-22 US$7.170 0.00% 1,132,505
26-10-21 US$7.170 -3.11% 945,330
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - REGENXBIO Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.580USD
Average target price
23.58USD
Spread / Average Target
+258.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - REGENXBIO Inc.
  1. Stock Market
  2. Stocks
  3. RGNX Stock